EpiVax Tregitope Technology: a Paradigm Shift

In any community of scientists, there are some who are bolder than most, who seek alternatives to existing paradigms because they perceive a path forward. Others will resist the alternative, which will be subject to scorn and scrutiny. In time, as the challenging paradigm is supported by additional evidence, it will replace the old paradigm, and a paradigm shift will have occurred. From: Thomas Kuhn, The Structure of Scientific Revolutions (1962).

  • Share ThisShareThis Email Contact Email PDF Version PDF Printer Friendly Version Print

Providence RI (Vocus) March 2, 2010

EpiVax, a paradigm-shifting biotechnology company, takes the road this spring to share news about Tregitope – the small peptides contained in IgG that trigger regulatory T cells – and other cutting-edge science and technology with scientific colleagues. Starting in Asia, EpiVax will be presenting the Tregitope paradigm shift at 10 conferences between March and August 2010. A list of upcoming conferences is presented here below.

3/21/10-4/1/2010: EpiAsia Tour: Tokyo, Osaka Tokyo, Osaka, Kobe, Tsukuba etc. (8 cities total); contact Dr. Keizo Yoshida for additional information.

4/26 – 4/28/2010: Thirteenth Annual NFID Conference on Vaccine Research; Bethesda MD. Method for Individualizing the Prediction of Immunogenicity for Vaccines and Protein Therapeutics: iTEM (individualized T Cell Epitope Measure).

5/16 – 5/19/2010: AAPS National BioTechnology Conference; San Francisco, CA. Preclinical Design of Less Immunogenic Biologics: Tregitopes and Tolerance; Hilton San Francisco Union Square.

5/16/2010: 3rd Annual Tregitope Collaborators Meeting; Boston, MA. (By invitation: contact spelletier(at)epivax(dot)com for more information).

5/17 – 5/18/2010: PEGS Immunogenicity of Therapeutic Biologics; Boston MA. Factors Driving Immunogenicity: The Science Sheraton Boston Hotel, Boston MA.

6/6 – 6/11/2010: Vaccine Technologies III; Vallarta, Mexico. Universal Flu Vaccines: Now more than Ever; Removal of tolerogenic signals from a dendritic cell targeting antibody; De-tolerization of anti-dec-205 for HIV subunit vaccine delivery; Personalizing Immune Responses to Vaccines, Autoantigens, and Protein Therapeutics: The iTEM (individualized T Cell Epitope Measure) Tool. Vallarta Palace Hotel, Nuevo Vallarta, Nayarit, Mexico.

6/13 – 6/17/2010: 46th DIA; Washington DC. Next Generation Biologics: Deimmunization and Tolerance Induction. Walter E. Washington Convention Center, Washington DC.

06/21 – 6/23/2010: IBC 1st annual immunogenicity; San Francisco, CA. Activation of Natural Regulatory T cells by IgG Fc-derived Peptide "Tregitopes". San Francisco Airport Marriott, Burlingame, CA

###

Share:

Contact